DeepMed Research

Changchun GeneScience Pharmaceutical Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Established: 1948-01-01

Employees: -

Market Cap: -

Website: http://english.ciac.cas.cn/

Clinical Trials

A Bioavailability Study of GS1-144 Tablets in Healthy Postmenopausal Women

Phase 1

Not yet recruiting

Conditions: Healthy Postmenopausal Women

Interventions: Drug: GS1-144 Tablet with new preparation (T)
Drug: GS1-144 Tablet with present preparation (R)

First Posted Date: 2025-05-21

Last Posted Date: 2025-05-21

Lead Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT06983925

Locations: 🇨🇳
Chengdu Xinhua Hospital, Chengdu, Sichuan, China

A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain

Phase 2

Not yet recruiting

Conditions: Endometriosis-related Pain

Interventions: Drug: GenSci048
Drug: Placebo

First Posted Date: 2025-05-08

Last Posted Date: 2025-05-08

Lead Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Target Recruit Count: 200

Registration Number: NCT06963177

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China

Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase

Phase 3

Not yet recruiting

Conditions: Extensive-stage Small Cell Lung Cancer (ES-SCLC)
The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy

Interventions: Drug: Nano-crystalline Megestrol Acetate Oral Suspension
Drug: standard treatment

First Posted Date: 2025-05-07

Last Posted Date: 2025-05-07

Lead Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Target Recruit Count: 94

Registration Number: NCT06961201

Locations: 🇨🇳
West China School of Medicine/West China Hospital of Sichuan University, Chengdu, Sichuan, China

Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis

Phase 3

Not yet recruiting

Conditions: Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity
Untreated With Systemic Therapy

Interventions: Drug: Nano-crystalline Megestrol Acetate Oral Suspension
Other: Standard Therapy

First Posted Date: 2025-05-07

Last Posted Date: 2025-05-07

Lead Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Target Recruit Count: 174

Registration Number: NCT06961188

Locations: 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors

Recruiting

Conditions: Cachexia
Digestive System Cancer
Gastric Cancer
Colorectal Cancer
Hepatocellular Carcinoma

Interventions: Drug: Nano-crystalline Megestrol Acetate Oral Suspension
Drug: TKI-Based Therapy

First Posted Date: 2025-04-23

Last Posted Date: 2025-04-23

Lead Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT06940102

Locations: 🇨🇳
General Hospital of Northern Theater Command, Shenyang, Liaoning, China
🇨🇳
Liaoning Cancer Hospital, Shenyang, Liaoning, China

A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation

Phase 1

Not yet recruiting

Conditions: Solid Tumors Harboring a TP53 Y220C Mutation

Interventions: Drug: GenSci128 tablets

First Posted Date: 2025-04-03

Last Posted Date: 2025-04-03

Lead Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Target Recruit Count: 82

Registration Number: NCT06908434

Locations: 🇨🇳
Zhongshan Hospital ,Fudan University, ShangHai, Shanghai, China

A Bioequivalence Study of Two Different Processes of PEG-rhGH Preparations

Phase 1

Not yet recruiting

Conditions: Pediatric Growth Hormone Deficiency (PGHD)

Interventions: Drug: PEG-rhGH with new preparation (T)
Drug: PEG-rhGH with present preparation (T)

First Posted Date: 2025-02-21

Last Posted Date: 2025-02-21

Lead Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Target Recruit Count: 87

Registration Number: NCT06840691

Locations: 🇨🇳
Chengdu Xinhua Hospital, Chengdu, Sichuan, China

Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue

Not Applicable

Recruiting

Conditions: Cancer-related Fatigue， Gastric Cancer，Colorectal Cancer，Nano-crystalline Megestrol Acetate，Megestrol Acetate，First-line Treatment

Interventions: Drug: Nano-crystalline Megestrol Acetate Oral Suspension
Combination Product: Standard Treatment

First Posted Date: 2025-02-17

Last Posted Date: 2025-02-17

Lead Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Target Recruit Count: 76

Registration Number: NCT06830018

Locations: 🇨🇳
The First Hospital Of China Medical University, Shenyang, Liaoning, China

A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults.

Phase 1

Recruiting

Conditions: Autoimmune Disease

Interventions: Drug: Placebo
Drug: GenSci120

First Posted Date: 2025-02-14

Last Posted Date: 2025-02-25

Lead Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Target Recruit Count: 56

Registration Number: NCT06827457

Locations: 🇨🇳
Huashan Hospital, Shanghai, Shanghai, China

A Bioequivalence Study of Two Different PEG-rhGH Preparations

Phase 1

Active, not recruiting

Conditions: Pediatric Growth Hormone Deficiency (PGHD)

Interventions: Drug: PEG-rhGH with new preparation (T)
Drug: PEG-rhGH with present preparation (T)

First Posted Date: 2025-01-28

Last Posted Date: 2025-04-09

Lead Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Target Recruit Count: 87

Registration Number: NCT06797505

Locations: 🇨🇳
Chengdu Xinhua Hospital, Chengdu, Sichuan, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy